Bright Peak Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $90M
Overview
Engineering optimized cytokine therapies for oncology and immunology applications.
ImmunologyOncology
Technology Platform
A proprietary protein engineering platform for designing optimized cytokine therapies, including cytokine-antibody fusions and pathway-biased variants, to improve safety and efficacy.
Funding History
1Total raised:$90M
Venture$90M
Opportunities
Revitalizing cytokine therapy, a class with proven efficacy but historical toxicity, for modern immuno-oncology and autoimmune treatment.
Risk Factors
Technical complexity in engineering functional cytokines and clinical risk of immune-related toxicity or lack of efficacy.
Competitive Landscape
Competes with a small set of specialized cytokine engineering companies and larger firms exploring immuno-oncology and immunology.